P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma

MLA

Remi Tilmont, et al. “P-277: Carfilzomib, Lenalidomide and Dexamethasone Followed by a Second Autologous Hematopoietic Cell Transplantation Is an Effective Strategy in First-Relapsed Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia, vol. 22, Aug. 2022, p. S190. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........954b92173febec9a63ebd148e5e0c6c2&authtype=sso&custid=ns315887.

APA

Remi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas Schaap, Concepcion Herrera Arroyo, Christine Schuermans, Wolfgang Bethge, Monika Engelhardt, Jürgen Kuball, Mariagrazia Michieli, Natalie Schub, Keith M.O. Wilson, Jean Henri Bourhis, María-Victoria Mateos, Neil Rabin, Edgar Jost, Nicolaus Kröger, … Salomon Manier. (2022). P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma. Clinical Lymphoma Myeloma and Leukemia, 22, S190.

Chicago

Remi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas Schaap, Concepcion Herrera Arroyo, et al. 2022. “P-277: Carfilzomib, Lenalidomide and Dexamethasone Followed by a Second Autologous Hematopoietic Cell Transplantation Is an Effective Strategy in First-Relapsed Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia 22 (August): S190. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........954b92173febec9a63ebd148e5e0c6c2&authtype=sso&custid=ns315887.